Past-Year Pap Testing Rates Were Lower in 2022 Than 2019
By Elana Gotkine HealthDay Reporter
FRIDAY, June 14, 2024 -- Past-year Papanicolaou testing rates were lower in 2022 than in 2019, overall, and lower rates were seen in rural versus urban women, according to a study published in online June 14 in JAMA Network Open.
Tyrone F. Borders, Ph.D., and Amanda Thaxton Wiggins, Ph.D., from the University of Kentucky in Lexington, examined receipt of a Papanicolaou test in the past year among U.S. women overall and in those residing in rural and urban areas in 2019, 2020, and 2022. Data were obtained from the Health Information National Trends Survey; study participants were women aged 21 to 65 years.
Of the 188,243,531 women included in the analysis, 12.5 and 87.5 percent lived in rural and urban areas, respectively. The researchers found that unadjusted past-year Papanicolaou testing rates were significantly lower among rural versus urban residents in 2022 (48.6 versus 64.0 percent). Compared with 2019, in 2022 adjusted odds of past-year Papanicolaou testing were lower (odds ratio, 0.70).
"Health care organizations, especially those serving rural females, should consider, at least temporarily, expanding access to Papanicolaou tests to increase cervical cancer screening rates to prepandemic levels," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Mailed Self-Collection Kits Increase Rates of Cervical Cancer Screening
WEDNESDAY, June 11, 2025 -- Mailed self-collection (SC) kits may increase participation in cervical cancer screening, according to a study published online June 6 in JAMA...
Parents Appear Receptive to Children Receiving HPV Vaccine at 9 or 10 Years of Age
MONDAY, June 2, 2025 -- Clinicians consider administration of human papillomavirus (HPV) vaccine as feasible at age 9 to 10 years, and parents appear to be receptive to discussing...
HPV Genome Sequencing Superior in Detecting Head & Neck Cancer
THURSDAY, May 29, 2025 -- Human papillomavirus (HPV) whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) detection has the highest sensitivity, specificity, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.